Kornimate/medical-research-clean huggingface dataset:
plantar faciitis and diabetes mellitus

Conditions: Diabetes Mellitus

Summary: obesity is a risk factor for calcaneal spur (cs) formation which is supposed to originate from chronic plantar fasciitis. diabetes mellitus may contribute to the risk of cs by decreased ability of tissue repair and increased reactive ossification. thus, the investigators aimed to determine cs incidence in asymptomatic obese subjects with and without type 2 diabetes mellitus (t2dm).

objective-obesity is a risk factor for calcaneal spur (cs) formation which is supposed to originate from chronic plantar fasciitis. diabetes mellitus may contribute to the risk of cs by decreased ability of tissue repair and increased reactive ossification. thus, the investigators aimed to determine cs incidence in asymptomatic obese subjects with and without type 2 diabetes mellitus (t2dm). research design and methods-ninety-three obese patients with t2dm and forty-two obese subjects without any metabolic disturbances as control were evaluated with lateral calcaneal x-ray in blinded fashion by a radiologist. all participants were informed and written consents have been obtained. control cases were subjected to 75g glucose challenge test and glucose intolerant subjects were excluded. results-t2dm and control groups were statistically similar in mean age (59±10.5 vs. 55±8 yrs, p=0.196, respectively) and mean body mass index (bmi)(35.1±4.3 vs. 33.1±3.3 kg/m2, p=0.073, respectively). existence of calcaneal spur was 72% in 93 patients (77%) in t2dm group and 24 in 42 (57%) in control group. groups were significantly different according to existence of cs (p=0.023). mean age and mean bmi were significantly higher in diabetic patients with calcaneal spur than diabetic patients without calcaneal spur (p=0.001 and p=0.015, respectively). there was positive correlation between existence of calcaneal spur and peripheral neuropathy (p=0,043) in diabetics but no significant relation between existence of cs and glycolysed hemoglobin levels or diabetes duration (all p\>0.05). conclusions-clinicians should pay attention the increased incidence of cs in patients with t2dm to avoid foot complications.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of diabetes mellitus * must be obese exclusion criteria: * previous radiotherapy to the foot, * previous trauma to the foot (fracture, rupture of tendon), * rheumatic or vascular diseases, * malign diseases, * lymphatic edema.

Keywords: calcaneal spur, diabetic obese patients
intervention study on hypertension management combined with health promotion at commune level

Conditions: Hypertension; Cardiovascular Risk Factor; Lifestyle

Summary: a quasi-experimental study design was chosen to compare the model of hypertension management at commune-level with conventional management for people with high blood pressure in two communes (one for intervention versus one for reference). a intervention model included the commune-based programme on hypertension management combined with comprehensive health promotion campaigns

a quasi-experimental study design was chosen: two communes were purposively selected from ba-vi setting: phu-phuong for reference and phu-cuong for intervention communes a hypertension management programme and the nested comprehensive health promotion campaigns were implemented simultaneously in phu-cuong while nothing performed in phu-phuong except for local conventional healthcare services. the health promotion campaigns aimed at smoking cessation, reduction of alcohol consumption, encourage of unsalted diet and physical activity, all of which targeted to every local inhabitants. the hypertension management programme focused on monthly check-ups, drug delivery and individual lifestyle consultation, all of which targeted to hypertensives only. baseline cross-sectional survey was used to assess cardiovascular pattern in local community before intervention and recruit people with high blood pressure for the management programme in intervention commune repeated cross-sectional surveys were used to evaluate the impacts of health promotion. cohort study on hypertensives was used to evaluate the impacts of the management programme.

Eligibility criteria:
inclusion criteria: * adult people above 25 exclusion criteria: * people deny to join the study

Keywords: hypertension cardiovascular risk factor lifestyle
patient reported outcomes in friedreich's ataxia patients after withdrawal from treatment with idebenone (proti)

Conditions: Friedreich's Ataxia

Summary: this is a phase iiib double-blind, randomised, placebo-controlled study. the aim is to further investigate the effects of idebenone in patients with friedreich's ataxia. the objective of the proti study is to establish whether patients can correctly determine which treatment assignment (placebo or idebenone) they received during the randomised phase of the trial, and identify any potential changes on symptoms or activities.


Eligibility criteria:
inclusion criteria: * completion of v5 (month 12), v6 (month 18), or v7 (month 24) in the miconos extension study * patients who in the opinion of the investigator are able to comply with the requirements of the study * body weight ≥ 25kg * negative urine pregnancy test exclusion criteria: * ae during the course of the miconos extension study which in the opinion of the investigator is attributable to idebenone and precludes further treatment with idebenone * clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal sgot, sgpt or creatinine * parallel participation in another clinical drug trial * pregnancy or breast-feeding * abuse of drugs or alcohol * any change of concomitant medication within the last 30 days that in the opinion of the investigator the intake could negatively impact the study

Keywords: randomized withdrawal idebenone friedreich's ataxia miconos patient reported outcome icars
long-chain fatty acid oxidation disorders online disease monitoring program

Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Summary: the objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the lc-faod community, by use of a convenient online platform for participants (or caregivers) to self-report information.

the online lc-faod dmp is a non-interventional, prospective, observational disease-monitoring program conducted through a mobile/web-based application developed by the sponsor. participant data will be captured via the mobile/web-based application and entered into the database designed and maintained by the sponsor and/or its designee. additional objectives of the study are to benefit the lc-faod community by developing a comprehensive database for use by the lc-faod community to characterize patient experience, inform disease management, and enable further research, utilize the digital platform to notify patients, caregivers, and relevant patient advocacy groups of research studies and clinical trials and share aggregated and de-identified outputs to facilitate the exchange of information with patients and/or caregivers. participants can be on any treatment in order to participate. medical management of the disease should continue as directed by the patient's physician(s). specifically, no treatments, investigational agents, or experimental interventions will be provided as part of this online lc-faod dmp.

Eligibility criteria:
inclusion criteria: * diagnosis of lc-faod including: carnitine palmitoyltransferase (cpt i or cpt ii) deficiency, very long chain acyl-coa dehydrogenase (vlcad) deficiency, long-chain 3-hydroxyacyl-coa dehydrogenase (lchad) deficiency, trifunctional protein (tfp) deficiency, or carnitine-acylcarnitine translocase (cact) deficiency. * willing and able to provide consent or, if a minor, provide assent and informed consent by their legally authorized representative. * access to the internet and an internet-enabled device. * reside in the geographical regions where the platform is supported and approved by applicable irb/iec and /or health authority. * not receiving triheptanoin through an ultragenyx-sponsored interventional clinical trial or ultragenyx investigator sponsored trial (ist). note: individuals are eligible to participate in this online dmp if they previously participated in ux007 clinical trials, are currently participating in the in clinic ux007-cl401 (nct04632953), are receiving triheptanoin through expanded access or compassionate use programs, or are receiving commercially available triheptanoin via prescription.

Keywords: cact deficiency carnitine acylcarnitine translocase deficiency long-chain 3-hydroxyacyl-coa dehydrogenase deficiency tfp deficiency trifunctional protein deficiency cpt1 cpt2 carnitine palmitoyltransferase deficiencies very long chain acyl coa dehydrogenase deficiency vlcad lchad cpt i cpt ii
complement activation and central nervous system injury after coronary artery surgery

Conditions: Coronary Artery Bypass Grafting

Summary: the impact of the postoperative inflammatory response on the central nervous system after cardiac surgery is uncertain. the goal of this study was to evaluate the role of complement activation on cellular brain injury and neurological functioning in patients undergoing coronary artery surgery. in addition, the effect of complement activation on the cerebral vasomotricity was assessed. because receptors to activated complement are present on astrocytes, the heparin-coated cardiopulmonary bypass that reduces complement activation should minimize these postoperative neurological adverse events. heparin-coating might also influence blood flow velocity in cerebral arteries postoperatively if complement activation mediates cardiopulmonary bypass induced cerebral vasomotor dysfunction.

closed cardiopulmonary bypass and controlled suctions of pericardial shed blood were standardized in all patients. bedside transcranial doppler examination served to evaluate the development of cerebral vasomotor dysfunction in a subgroup of patients.

Eligibility criteria:
inclusion criteria: * men undergoing coronary artery bypass surgery using cardiopulmonary bypass exclusion criteria: * clinical conditions expected to potentially influence the magnitude of the systemic inflammatory response after surgery such as open heart surgery, women because they show higher complement activation after surgery, redo cases, organ dysfunction as defined by the euroscore such as chronic airway disease or renal dysfunction with creatinine level above 200 µmol/l, patients with left ventricular ejection fraction below 35%, diabetes mellitus under insulin therapy prior to the operation, presence of active inflammatory disease or patients taking anti-inflammatory drugs (except acetylsalicylic acid). * significant carotid artery stenoses (\>70%) at the preoperative echo-doppler examination, evidence of preexisting neurologic or psychiatric disease, existence of preoperative neuropsychological impairment as defined by preoperative mini-mental state examination (mmse) below 27, and alcohol addiction.

Keywords: cardiopulmonary bypass, inflammatory response neurologic injury neurocognitive deficit biomaterials coronary artery bypass surgery
ultrasound guided rectus sheath block versus intrathecal morphine for postoperative analgesia in patients undergoing open total abdominal hysterectomy

Conditions: Ultrasound; Rectus Sheath Block; Intrathecal Morphine; Postoperative Analgesia; Total Abdominal Hysterectomy

Summary: this study aims to compare the effectiveness and safety of ultrasound-guided rectus sheath block versus intrathecal morphine for postoperative analgesia in patients undergoing open total abdominal hysterectomy.

effective postoperative analgesia is crucial for enhancing recovery and patient satisfaction following major surgical procedures, such as total abdominal hysterectomy (tah). rectus sheath block (rsb), an ultrasound-guided regional anesthesia technique, involves the injection of local anesthetic into the rectus sheath, providing analgesia to the anterior abdominal wall. rsb is used to block the sensory nerves of the anterior abdominal wall and thereby contributing to pain relief after lower abdominal surgeries. intrathecal morphine (itm) provides a highly effective method of analgesia by delivering the medication directly into the cerebrospinal fluid (csf).

Eligibility criteria:
inclusion criteria: * age: 18 - 65 years old. * american society of anesthesiologists (asa) physical status (i -ii). * patients undergoing open total abdominal hysterectomy. exclusion criteria: * hepatic, renal, or cardiac disease. * any known allergy to local anesthetic. * physical or mental conditions which may vague measuring postoperative pain following surgery. * history of chronic use of analgesic as nonsteroidal anti-inflammatory drugs (nsaids) or central nervous system (cns) depressants as antiepileptic, and bleeding disorders.
efficacy and safety of cinacalcet in ca, p and ipth levels in patients with mild, moderate and severe shpt

Conditions: Hyperparathyroidism; Secondary, Renal

Summary: 1. to evaluate achievement ratio of ipth,calcium and phosphorus after taking cinacalcet hcl in hemodialysis subjects with mild, moderate and severe shpt; 2. to explore the impact of cinacalcet hcl using on the combined use of drugs; 3. to explore the difference of patients who continued or discontinued cinacalcet hcl in real-world period from 33rd to 52nd week.


Eligibility criteria:
inclusion criteria: - parents/guardians must sign informed consent; must be males or females whose age are 18 to 75 years old; clinical diagnosis of chronic kidney disease on maintenance hemodialysis with secondary hyperparathyroidism; ipth must be equal or higher than 300pg/ml; must not have received calcimimetics(for example, cinacalcet) within 6 months prior to enrollment; must have been on maintenance hemodialysis 3 times weekly (tiw) for at least 3 months(12 weeks) prior to enrollment and must be expected to remain on hemodialysis for the duration of the study; over 2-year life expectancy. exclusion criteria: - hypocalcemia \[corrected serum calcium level less than 2.1mmol/l(8.4mg/dl); history of gastrointestinal bleeding or peptic ulcer disease and possibility of deterioration or recurrence; severe heart disease; epilepsy risk or history of epilepsy; hypersensitivity to cinacalcet; drug abuse/addiction; plan to receive renal transplantation within 52 weeks; pregnant or lactating women; pregnancy plan within 1 years, or no guarantee on taking effective contraceptive measures within 1 year after enrollment; participated in other clinical trials within 4 weeks prior to enrollment; received parathyroidectomy within 24 weeks prior to enrollment; investigator judgment that patients are not suitable to enroll.

Keywords: cinacalcet secondary hyperparathyroidism calcimimetics ckd-mbd
amsc for reducing anastomotic stenosis in primary arteriovenous anastomoses

Conditions: End Stage Renal Disease

Summary: researchers are evaluating the safety of allogeneic adipose derived mesenchymal stem cells (amsc) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.


Eligibility criteria:
inclusion criteria: * patient between 18 and 85 years old * patient currently planned for creation of an upper extremity av fistula with suitable anatomy * ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures * life expectancy of at least 24 months * if female, must be post-menopausal or not able to have children. post-menopausal/non-child bearing status must be clearly documented in the medical record. if documentation of post-menopausal/non-child bearing status is not available then a pregnancy test must be performed. exclusion criteria: * malignancy or treatment for malignancy within the previous 6 months * immunodeficiency including aids / hiv or active autoimmune disease * documented hypercoagulable state or history of 2 or more dvts or other spontaneous intravascular thrombotic events * treatment with any investigational drug/ device within 60 days prior to study entry or any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of amscs and the avf * history of failed organ transplant on immunosuppression. * subjects with known active infection (infection which is being treated)
neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation for stage iiic cervical cancer patients: a randomized phase iii trial

Conditions: Cervical Cancer; Neoadjuvant Chemotherapy; Bulky Neoplasm

Summary: evaluate the efficacy and safety of neoadjuvant chemotherapy (nac) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (crt) for stage iiic cervical cancer patients with carcinoma \>4 cm in greatest dimension and/or lymph node \>2cm in short axis.

in this phase iii tiral , stage iiic cervical cancer patients with carcinoma \>4 cm in greatest dimension and/or lymph node \>2cm in short axis will be randomly assigned to two circles of nac with albumin-bound paclitaxel and carboplatin followed by standard crt with weekly cisplatin plus pelvic radiotherapy or to standard crt alone. the primary end point was 3-year progression-free survival (pfs). secondary end points were response rate, 3-year locoregional control, 3-year overall survival (os), safety, and quality of life.

Eligibility criteria:
inclusion criteria: 1. pathologically comfirmed : squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix； 2. figo (2018 international federation of gynecology and obstetrics) stage iiic with carcinoma \>4 cm in greatest dimension and/or lymph node \>2 cm in short axis at initial diagnosis. 3. age 18 to 70 years； 4. eastern cooperative oncology group performance status 0 to 2； 5. adequate organ function. exclusion criteria: 1. not at initial diagnosis; 2. with other kind of tumor. -

Keywords: cervical cancer neoadjuvant chemotherapy bulky neoplasm
comparison of an internet-based guided self-help and a group therapy for chronic tinnitus

Conditions: Tinnitus

Summary: the aim of this study is to compare the efficacy of an internet-based guided self-help training for chronic tinnitus with a well-established outpatient group therapy and a discussion forum group.

chronic tinnitus can result in significant psychological suffering and reduce quality of life. cognitive behavioral therapy (cbt) has been shown to be effective in decreasing the impairment caused by tinnitus. one recent way delivering cbt is an internet-based self-help intervention. internet interventions for patients with chronic tinnitus, developed by swedish scientists, showed promising results (andersson et al., 2002; kaldo et al., 2007; kaldo et al., 2008). the main purpose of this study is to compare the efficacy of this internet-based self-help training for chronic tinnitus with a traditional well-established cbt group treatment and with a discussion forum group in a randomized controlled trial. secondary goals are a process evaluation of both treatments, the identification of predictors of treatment success, an estimation of the cost-effectiveness of each treatment and the validation of the tinnitus cognitions questionnaire (t-cog; hiller \& haerkötter, 2005).

Eligibility criteria:
inclusion criteria: * age of at least 18 years * chronic tinnitus for at least 6 months * medical examination of tinnitus by an ear, nose and throat physician (ent) * scoring 18 or above on the tinnitus handicap inventory (thi) or scoring 12 or above in the mini-tinnitus questionnaire (mini-tq) * not currently receiving psychological treatment for tinnitus * being able to access the internet and print instructions * sufficient knowledge of the german language to read and follow the internet-based self-help training * being able to attend weekly group sessions in the outpatient department of the psychological institute of the university of mainz, germany * sufficient time and motivation to work on the treatment programs exclusion criteria: * tinnitus caused by any other general medical condition or otologic disease (e.g., active meniere's disease) * clinical diagnosis of any severe mental disorder (especially a severe depressive disorder, suicidality, acute psychosis) * clinical diagnosis of dementia or another severe organic cerebral disorder * clinical diagnosis of substance-related addiction/abuse

Keywords: tinnitus internet training cognitive-behavior therapy cbt
american migraine prevention study

Conditions: Migraine Disorders

Summary: the purpose of this study is to evaluate the use of nutritional supplementation and dietary management for the reduction in frequency, duration, and intensity of migraine headache pain.

amps, the american migraine prevention study program is a home based nutritional study for migraine prevention. it is designed to evaluate a nutritional supplement along with proper diet, and trigger management that may prevent migraines or reduce the frequency, duration and intensity of migraine headache pain. the amps program is availalbe nationwide. it is a home based study program. during the three month study period, participants will be asked to take a daily nutritional supplement and follow a recommended diet to avoid potential migraine triggers. participants will be asked to maintain a headache log and submit headache questionnaires at the beginning and end of the study. participants do not have to travel and can participate from their current location.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of migraines * ages 18-72 * migraines more than once per month * diagnosed migraines for more than one year exclusion criteria: * pregnant/nursing

Keywords: nutritional c10.228.140.546.399.750
serum hs-crp in periodontitis patients with or without diabetes

Conditions: Periodontal Disease; Diabetes Mellitus, Type 2

Summary: the aim of this study was to assess serum levels of high sensitivity c reactive protein in periodontitis patients with and without type 2 diabetes in a trial to analyze its prognostic effect following non-surgical periodontal therapy.

periodontitis and diabetes are chronic disorders with a two-way correlation as they can both stimulate an inflammatory response with subsequent formation of inflammatory mediators and cytokines. c reactive protein is an inflammatory plasma marker having a role in the systemic reaction to inflammation. thus, our aim in the current study was to evaluate serum levels of high sensitivity c reactive protein in periodontitis patients with and without type 2 diabetes in a trial to analyze its prognostic effect following non-surgical periodontal therapy. a total of 60 patients were enrolled in this study. elisa was used for determination of hs- crp. non- surgical periodontal therapy was carried out for all periodontitis patients.

Eligibility criteria:
inclusion criteria: 1. diabetic patients type 2 2. periodontitis patients exclusion criteria: 1. smokers 2. pregnant females